Coloplast A/S

Copenhagen Stock Exchange COLO-B.CO

Coloplast A/S Operating Cash Flow for the year ending September 30, 2024: USD 412.77 M

Coloplast A/S Operating Cash Flow is USD 412.77 M for the year ending September 30, 2024, a -30.92% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Coloplast A/S Operating Cash Flow for the year ending September 30, 2023 was USD 597.56 M, a -10.81% change year over year.
  • Coloplast A/S Operating Cash Flow for the year ending September 30, 2022 was USD 670.01 M, a -18.66% change year over year.
  • Coloplast A/S Operating Cash Flow for the year ending September 30, 2021 was USD 823.71 M, a 9.94% change year over year.
  • Coloplast A/S Operating Cash Flow for the year ending September 30, 2020 was USD 749.21 M, a 18.10% change year over year.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
Loading...
Copenhagen Stock Exchange: COLO-B.CO

Coloplast A/S

CEO Mr. Kristian Villumsen
IPO Date Jan. 2, 2000
Location Denmark
Headquarters Holtedam 1-3
Employees 16,639
Sector Health Care
Industries
Description

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

Similar companies

DSV.CO

DSV A/S

USD 204.21

-1.25%

AMBU-B.CO

Ambu A/S

USD 18.73

1.26%

GN.CO

GN Store Nord A/S

USD 17.06

1.00%

StockViz Staff

January 15, 2025

Any question? Send us an email